Go See Improved Adult Stem Cell Circulation … morris.stemtechbiz.com …Now… with the new Adult Stem cell Circulation Enhancer Capsules… Stem Cell Nutrition will better aid the circulation and help with getting oxygen to all parts of the body! Stem Cell Circulation Enhancer capsules are a new phytoceutical product, that can help improve stem cell trafficking. Powerful antioxidants help reduce the oxidative stress in the body’s blood physiology, reducing the formation of fibrin mesh: and contains a blend of enzymes that help digest the fibrin within the blood. This combination helps support optimizing a more free-flowing circulation. Along with nutrients .. this stem cell circulation formula supports the delivery of nutrients and oxygen to the body as well as the stem cells!

Part 1: Dr. Riordan discusses mesenchymal stem cell sources from umbilical cord Wharton’s jelly, stem cell expansion, therapeutic potential of umbilical cord mesenchymal stem cells vs. bone marrow mesenchymal stem cells, CD34+ hematopoietic stem cells from umbilical cord blood and the scientific rationale supporting stem cell treatment of spinal cord injury

The company, Osiris Therapeutics of Columbia, Md., said Thursday that Canadian regulators had approved its drug Prochymal, to treat children suffering from graft-versus-host disease, a potentially deadly complication of bone marrow transplantation.

“It’s really a good day for the concept and the hope behind stem cell therapies becoming a reality,” C. Randal Mills, the chief executive of Osiris, said in an interview.

Prochymal is a preparation of mesenchymal stem cells, which are obtained from the bone marrow of healthy young adult donors. The stem cells are separated out from the marrow and expanded in culture, so that one donation is enough to make as many as 10,000 doses.

Because these are adult stem cells, they do not raise the ethical concerns of embryonic stem cells, whose creation usually involves the destruction of human embryos.

Graft-versus-host disease occurs when the immune cells in a bone-marrow transplant see the recipient’s organs as foreign and attack them, causing potentially severe damage to the skin, liver and digestive tract. This happens most often when the donor is not an exact match for the recipient.

Doctors try using steroids or other drugs to damp the immune attack, but in many cases those don’t work, and the patient may die.

Prochymal is approved in Canada for children whose condition is not controlled by steroids. In a small trial, about 60 percent of such children had a clinically meaningful response to the drug, Osiris said.

“Any drug or a cell that has activity in the patients with severe disease is exciting and important,” said Dr. Joanne Kurtzberg, director of the pediatric blood and marrow transplant program at Duke University Medical Center.

Dr. Kurtzberg, who helped Osiris present its case to Canadian regulators, said the drug has saved some children’s lives from graft-versus-host disease and could lead to more successful bone marrow transplants.

Osiris is not expected to gain much revenue from patients with a rare disease in Canada. But it is a welcome success for a 20-year-old company that has had its share of failures.

In 2009, Prochymal failed in two late-stage clinical trials, showing little to no advantage over placebo in treating graft-versus-host disease. The company is also trying to develop Prochymal as a treatment for Crohn’s disease, diabetes, heart attacks and other illnesses, but has had some failures there as well.

Sanofi, the big French company that had the rights to sell Prochymal outside North America, said in February that it had discontinued its work on the drug.

Dr. Mills, Osiris’s chief executive, said the company realized the drug was most effective in the most severe cases of graft-versus-host-disease that did not respond to steroids, leading it to do the small trial in children.

Dr. Mills said that the Food and Drug Administration indicated that it would require more data before approval, prompting Osiris to seek approval in Canada first. He said the company would apply to the F.D.A. later this year.

Stem cells are already used in medicine. Bone marrow or stem cell transplants are used to treat various cancers and genetic diseases. But those transplants are medical procedures, not products sold by a drug company.

There are cell therapies that have been approved by regulators, such as Carticel, a Genzyme product that uses a patient’s own cells to repair cartilage in injuries. Last year the F.D.A. approved a cord blood product for use in transplantation. Those products are not manufactured for off-the-shelf use like Prochymal is, Dr. Mills said.

Cody’s Stem Cell Therapy Day 2 at The Stem Cell Institute, Panama City, Panama

Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Som

Rating: (out of reviews)

List Price: $ 239.00

Price:

Related “stem Cell Transplantation ” Products

Witness Releasing Millions MORE Adult Stem Cells Naturally .. go to EJMorris.biz .. If a person stimulates the body to Release MORE stem cells from the bone marrow, the body would likely be able to repair and renew itself, at a balanced.. or Faster pace than it might by dying. Negative changes in the body, due to illness, accident or simply going through process of aging.. results in less adult stem cells circulating in the blood stream. Investigate All your adult stem cell therapy options, including patented natural adult stem cell enhancer capsules and the category of adult stem cell nutrition. Fact The more adult stem cells in the bloodstream are, the better it is for the body.. the closer you are to achieving optimal health. Fact: The older the body becomes.. MORE adult Stem Cells are required for repair and Renewal. And, the sad fact is.. as the body AGES .. the body has LESS stem cells in blood circulation for renewal ,repair and rejuvenation. The World’s FIRST Adult stem cell nutrition that releases, into circulation into the blood stream, millions more adult stem cells that are “Stuck” in the bone marrow is phenomenon that adult stem cell scientists and researchers have discovered. It has been proven our OWN adult stem cells.. the stem cells that are present in our body from the Minute we are born, constitute our body’s natural RENEWAL SYSTEM. Witness the world’s first adult stem cell enhancer nutrition products available in capsules, tablets, powders, granules …

www.globalchange.com Repair retina damaged by macular degeneration in the eye. Retinal regeneration using adult stem cells – research and early clinical trials. Other studies using embryonic stem cells to partially restore sight in those with visual impairment blindness. Use of adult neural stem cells from the olfactory bulb to treat brain disease, brain injury or spinal cord injury, paralysis. Antiageing therapies, science and research. 65% of health care spending on people over 65 years old. Aging process — physiology of aging and remedies, antiaging therapies. How to stay young. How we share common aging and regenerative processes with many other animals. Shared genetic code and cell structures. From health to performance, from sickness to wellness, from prevention to appearance, from rehabilitation to organ regeneration. Future of health care. Patrick Dixon is a health care keynote speaker at many health conferences.

Stem cells are the body’s repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few. With this capability, we can use them as a treatment for joint injuries, ligament and tendon damage, and fractured bones. Using MediVet America’s Stem Cell Therapy, we have seen positive clinical improvement in 95% of the arthritic cases performed nationwide. Some owners have even reported seeing a difference in as little as a week!

Dr Foteini Hassiotou and the Hartmann Human Lactation Research Group at the University of Western Australia have found stem cells in human breast milk that they have turned into bone, brain, liver, and pancreatic cells that produce insulin.

From ABCScience.com:

A solution to the ethical dilemma of using human embryonic stem cells to treat human diseases could be staring us in the face.

Five years ago, Dr Foteini Hassiotou was part of a research team, the Hartmann Human Lactation Research Group at the University of Western Australia, which discovered that human breast milk contains what appear to be stem cells. These cells can potentially turn into many different types of cells, and offer staggering potential for treating a huge range of human diseases.

Hassiotou, the newest member of the group, found that some of these stem cells are very similar to embryonic stem cells — the most potent and useful stem cell of all.

Except the “potent and useful” stem cells found in breast milk do not require the destruction of human embryos to harvest them like embryonic stem cells. The stem cells in human breast milk are easily collected without surgery. The next step would be to investigate how these adult stem cells behave in animal models.

Human breast milk may be more than just nourishment for newborns. It may contain hope for a multitude of diseases. Hope that does not require the destruction of innocent human life.

Regenerative Sciences’ Regenexx procedures utilize a patient’s own stem cells to help repair a broad range of common injuries and degenerative conditions, including cartilage lesions, torn ligaments and tendons, osteoarthritis and bulging spinal discs. For many, the procedures offer a viable alternative to arthroscopic surgery, open-joint surgery, or joint replacement surgery. Regenexx patients experience little or no downtime from the procedures and avoid the lengthy rehabilitation period associated with most surgical procedures.

“We are proud of our accomplishments in the field of regenerative interventional orthopedics and it’s exciting that our work has drawn the attention of such a noted entrepreneur and philanthropist,” said Christopher J. Centeno, M.D., Chief Executive Officer of Regenerative Sciences. “Dr. Malone shares our vision for forging the next generation of minimally invasive regenerative treatments. This investment will not only bolster our existing stem cell research programs and make our procedures available in all regions of the U.S., but it will help us maintain a leadership role in clarifying the regulatory space for physician stem cell use.”

Regenerative Sciences is at the forefront of regenerative orthopedic medicine within the United States and the company is bringing the future of orthopedic treatments to patient care today.

About Regenerative Sciences

Regenerative Sciences is an outgrowth of the Centeno-Schultz clinic, where we are reinventing orthopedic care for the 21st century using key biologics such as stem cells, next generation tools and devices, and unique therapeutic approaches. Our signature initiative, Interventional Orthopedics, allows doctors to treat orthopedic conditions through injection, rather than traditional invasive surgery. The Regenexx Physician Network brings together like-minded physicians from around the country to offer more patients access to our innovative procedures. For more information on Regenerative Sciences and Regenexx procedures, visit: www.regenexx.com

About John C. Malone, PhD

Dr. John C. Malone holds a bachelor’s degree in electrical engineering and economics from Yale University, where he was a Phi Beta Kappa and merit scholar. He also holds a master’s degree in industrial management and a Ph.D. in operations research from Johns Hopkins University.

Dr. Malone is Chairman of Liberty Media Corporation, a position he has held since 1990. Dr. Malone is also the Chairman of the Board of Liberty Global, Inc. (LGI), a position he has held since June, 2005. From 1996 to March 1999 when Tele-Communications, Inc. (TCI) merged with AT&T Corp., he was also Chairman and Chief Executive Officer of TCI. Previous to that, from 1973 to 1996, Dr. Malone served as President and CEO of TCI. He currently serves on the Board of Directors for CATO Institute, Expedia, Inc., Discovery Communications, Inc., and SiriusXM.